|
|
 |
 |
 |
|
|
|||
|
||||
|
||||
Perinatal HIV transmissionFrom: Amarnath Bhide (amarnath@bom2.vsnl.net.in)Sun Aug 2 07:24:44 1998
Dear Listmembers, I want your reaction to the article published in JAMA recently, Interaction between zidovudine prophylaxis and mode of delivery in the French perinatal trial (JAMA, 1998, 280:55-60) LSCS seems to reduce the perinatal transmission only when combined with AZT. Why should that be? In patients not receiving AZT(n17), mode of delivery was not related to the outcome. In patients receiving AZT, and el. CS, the transmission rate was 0.8% (1/133). Transfer of the virus has been known in as many as 30% of the abortuses, still with this protocol, maternal-foetal transmission was just 0.8%. Should we start offering el. CS to our patients on AZT? Is there any literature on response to multidrug therapy for advanced HIV in women who have earlier received AZT for reducing perinatal transmission? Does the therapy works as well, or there is development of resistance? Thanks. Dr. Amarnath Bhide MD, MRCOG, DNB Associate Professor, Seth G.S. medical College and N. Wadia Maternity Hospital, Bombay, India.
|
|
Return to
|
Mail a New Message to the Forum: ob-gyn-l@obgyn.net Forum Administrator: geffrey.klein@obgyn.net Report Technical Problems: webmaster@obgyn.net Last Updated: Wed Dec 2 05:25:07 2009 |
The American Medical Association is no longer designating CME hours for AMA Category II CME credit. However, physicians themselves may self designate learning activities as Category II CME credit hours if they feel it is of sufficient educational merit and meets the formal definitions of continuing medical education. OBGYN.net believes these interaction in this forum meets these criteria. For further information see the AMA web site.